NCT03641794View on ClinicalTrials.gov

Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers

PHASE1UnknownINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

September 7, 2018

Primary Completion Date

May 13, 2019

Study Completion Date

July 31, 2019

Conditions
Advanced Solid Tumors
Interventions
DRUG

DN1406131

IDO1 and TDO2 inhibitor

DRUG

Placebo

Placebo

Trial Locations (1)

255000

RECRUITING

PKUCare Luzhong Hospital, Zibo

Sponsors
All Listed Sponsors
collaborator

Shanghai De Novo Pharmatech Co., Ltd.

INDUSTRY

lead

Jiangxi Qingfeng Pharmaceutical Co. Ltd.

INDUSTRY